secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001213900-26-049338
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 3.02, 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology ships first international order of LYMPHIR to Europe
--------------------------------------------------------------------

- First international shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe through a regional distribution partner.
- Product will be available via Named Patient Programs under applicable local regulations.
- LYMPHIR approved by FDA in August 2024 for relapsed/refractory CTCL; U.S. commercial launch in December 2025.
- Citius Oncology (Nasdaq: CTOR) is a majority-owned subsidiary of Citius Pharmaceuticals (CTXR).
- International expansion complements ongoing U.S. launch progress with formulary access and payer coverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026049338/0001213900-26-049338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390026049338/ea0288203-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-049338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer